BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34627500)

  • 21. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
    Barr R; Robertson J
    Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential medicines out of reach for most people.
    Indian J Med Sci; 2008 Dec; 62(12):520-1. PubMed ID: 19402257
    [No Abstract]   [Full Text] [Related]  

  • 23. Ensuring access to essential medicines: some economic considerations.
    Maskus KE
    Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162
    [No Abstract]   [Full Text] [Related]  

  • 24. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 25. Access to essential medicines to treat chronic respiratory disease in low-income countries.
    Bissell K; Perrin C; Beran D
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study.
    Stolbrink M; Ozoh OB; Halpin DMG; Nightingale R; Meghji J; Plum C; Allwood BW; Jayasooriya S; Mortimer K;
    Thorax; 2024 Jun; 79(7):676-679. PubMed ID: 38760170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What does it mean to put new hepatitis C drugs on a list of essential medicines?
    Urrutia J; Porteny T; Daniels N
    BMJ; 2016 Apr; 353():i2035. PubMed ID: 27106956
    [No Abstract]   [Full Text] [Related]  

  • 28. Unfunded promises as the UK health debate takes centre stage.
    Lancet Oncol; 2010 May; 11(5):401. PubMed ID: 20409754
    [No Abstract]   [Full Text] [Related]  

  • 29. The selection and use of essential medicines. Report of the WHO expert committee, 2005 (including the 14th model list of essential medicines).
    World Health Organ Tech Rep Ser; 2006; (933):1-119, back cover. PubMed ID: 17566509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in availability of cancer drugs across Europe.
    Mayor S
    Lancet Oncol; 2016 Sep; 17(9):1196. PubMed ID: 27476616
    [No Abstract]   [Full Text] [Related]  

  • 31. Consortium Outlines 3 Solutions to Maximize the Benefit and Affordability of Targeted Cancer Drugs.
    Cancer; 2018 Aug; 124(16):3283. PubMed ID: 30141838
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to medicines versus access to treatment: the case of type 1 diabetes.
    Beran D; McCabe A; Yudkin JS
    Bull World Health Organ; 2008 Aug; 86(8):648-9. PubMed ID: 18797626
    [No Abstract]   [Full Text] [Related]  

  • 34. The selection and use of essential medicines.
    WHO Expert Committee
    World Health Organ Tech Rep Ser; 2008; (950):backcover, vii-174. PubMed ID: 18754303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The high price of cancer drugs: enough is enough.
    Prescrire Int; 2015 Jan; 24(156):27. PubMed ID: 25729840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Policies and programs to facilitate access to targeted cancer therapies in Thailand.
    Sruamsiri R; Ross-Degnan D; Lu CY; Chaiyakunapruk N; Wagner AK
    PLoS One; 2015; 10(3):e0119945. PubMed ID: 25798948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 39. Innovation and the WHO's essential medicines list: giving credit where credit is due.
    Wertheimer AI; Santella TM
    Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
    [No Abstract]   [Full Text] [Related]  

  • 40. Country and regional variations in purchase prices for essential cancer medications.
    Cuomo RE; Seidman RL; Mackey TK
    BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.